Dr Marg Ewen Receives the Helen Clark-JoPPP Award

No Universal Health Coverage without Universal Medicines Coverage


A Year at the Heart of Regulatory Decision Making

Staff Spotlight: Jaume Vidal

Time for a Treaty? ReAct Reports on Second Consultation on Global Development & Stewardship Framework to Combat AMR

Medicijnen: de link met de maatschappij

What Role Can Civil Society Play in the European Regulatory Process?

Open Science for Health: Shaping the New Framework Programme


EU-Mercosur Trade Agreement: A bad deal for transparency, policy coherence and access to medicines

New Dutch Government Must Ensure Transparency to Control Medicine Prices

Staff Spotlight: Tim Reed

European Commission Appoints Health Action International to HTA Network Stakeholder Pool


Clinical Trial Data Transparency on Trial – EMA Under Pressure From Pharma Lawsuit

Next Gen Advocates Excel at HAI/HP4L Summer School on Access to Medicines

Farewell to Access to Medicines Pioneer, Andrew Herxheimer


HAI/WHO Pharmaceutical Promotion Manual Still Key to Combating Promotion around the World

HAI Holds Workshops on EU Medicines Policy & Access to Medicines in Eastern Europe

HAI urges MEPs to support key amendments to TTIP resolution

The EU-US Trade Deal Could Leave Europeans Sick


More work needed on new EMA conflicts of interest policy

EMA policy on clinical data publication a step ahead, but falls short of true potential

Abysmal decisions: Why the EC’s medicinal units shouldn’t be moved to DG Industry

Democracy violation: European Commission rejects citizens’ initiative to stop TTIP and CETA

School's IN for summer: HAI staff and interns inspired by Utrecht University's course on pharmaceutical policy analysis

Setting precedents: EMA must get clinical trial data policy right to truly act in public interest

HAI Europe calls on EMA's Management Board to stand for data transparency

Tamiflu review shows desperate need for full clinical trials data transparency

A new (and improved) model to regulate pharmaceutical promotion

Bayer CEO's callous comments highlight failure of current biomedical innovation model


When politicians go to the movies